An interview with Professor Marcin Wojnar, head of the Department of Psychiatry at the Medical University of Warsaw.
Psychiatrists stress that when we talk about the introduction of a drug program in drug-resistant depression, using esketamine, we are talking about a breakthrough. Why is this so important from the point of view of clinicians, but also their patients?
First, it is worth emphasizing what this breakthrough will consist of, and this will justify why we have waited so long for it. Standard treatment with antidepressants usually has to last several weeks before the patient shows improvement. Another few before complete remission occurs. And given this dysfunction or functioning problems and the level of suffering that depre...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
